PuneetSCheemaMD

Oncology • Maplewood, MN

Physician

Join to view full profile

Dr. Cheema is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cheema's full profile

Already have an account?

Office
1575 Beam Ave
Maplewood, MN 55109
Phone+1 651-232-7970

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 1999 - 2002
Rush University Medical CenterResidency, Internal Medicine, 1996 - 1999
Government Medical College AmritsarClass of 1995

Certifications & Licensure

AR State Medical License 1999 - 2026
FL State Medical License 2022 - 2025
MN State Medical License 2006 - 2025
TX State Medical License 2022 - 2025
WI State Medical License 2003 - 2025
IL State Medical License 1996 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Canc...
Rachna T Shroff, Gentry King, Sarah Colby, Aaron J Scott, Mitesh J Borad
Journal of Clinical Oncology. 2024-12-13
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Vered Stearns, Anne ONeill, Bryan P Schneider, Todd C Skaar, Minetta C Liu
Breast Cancer Research and Treatment. 2024-10-21
22 citations
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Rami S. Komrokji
Journal of Clinical Oncology. 2021-01-13

Abstracts/Posters

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Puneet S. Cheema, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019